The patents relate to a specific isolated stem cell derived from human brown adipose tissue that's capable of differentiating into multiple cell types. These cells have potential therapeutic uses for treating a wide range of degenerative and metabolic disorders.

The ThermoStem platform technology can be used to develop cell-based therapy candidates that mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.

The notices of allowances cover the U.S., Israel, France, Germany, Italy, Spain, and the U.K. The applications have been issued or are expected to issue as patents in 2021.